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Abstract
Background: Associations between body mass index (BMI), outcome, and leuke-
mia‐related factors in children with acute myeloid leukemia (AML) remain unclear. 
We investigated associations between pretherapeutic BMI, cytogenetic abnormali-
ties, and outcome in a large multinational cohort of children with AML.
Methods: We included patients, age 2‐17 years, diagnosed with de novo AML from 
the five Nordic countries (2004‐2016), Hong Kong (2007‐2016), the Netherlands and 
Belgium (2010‐2016), and Canada and USA (1995‐2012). BMI standard deviations 
score for age and sex was calculated and categorized according to the World Health 
Organization. Cumulative incidence functions, Kaplan‐Meier estimator, Cox regres-
sion, and logistic regression were used to investigate associations.
Results: In total, 867 patients were included. The median age was 10 years (range 
2‐17 years). At diagnosis, 32 (4%) were underweight, 632 (73%) were healthy weight, 
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1 |  INTRODUCTION
Acute myeloid leukemia (AML) in children is a clinically 
and genetically heterogeneous disease with a long‐term 
overall survival of around 70%, and few known causative 
factors.1,2 Overweight in children is increasing globally 
and, as a consequence, so are overweight‐related diseases.3 
Among children with AML, it is important to understand 
if overweight patients have different outcomes and leuke-
mia‐related features. Overweight at diagnosis has been as-
sociated with inferior outcome in pediatric AML in two 
North American studies,4,5 but in a recent study on mainly 
Nordic patients, we failed to confirm this association.6 
Likewise, results from studies on the effect of pretherapeu-
tic body mass‐index (BMI) in adults with AML have been 
conflicting.7-9 In our previous study, we saw indications of 
cytogenetic abnormalities being associated with weight‐
group,6 an association that, to our knowledge, has not been 
reported in children before.
In this study, we aimed to investigate associations between 
pretherapeutic BMI and outcome in a large, multinational co-
hort of children diagnosed with AML and treated on several 
protocols. Second, we aimed to confirm a possible associ-
ation between BMI group and cytogenetic abnormalities as 
suggested by our previous study.
2 |  MATERIALS AND METHODS
2.1 | Patients
We included patients less than 18 years of age diagnosed with 
de novo AML before November 1st 2016, but without Down 
syndrome, acute promyelocytic leukemia, or isolated gran-
ulocytic sarcoma. Patients originated from the five Nordic 
countries (Sweden, Denmark, Norway, Finland and Iceland), 
the Netherlands, Belgium, Hong Kong (NOPHO‐DBH 
cohort) and Canada and USA. Included patients from the 
Nordic countries were diagnosed from 2004 to 2016, Hong 
Kong from 2007 to 2016, Belgium and the Netherlands from 
2010 to 2016, Canada from 1995 to 2012 and USA from 
2005 to 2012. Included patients from Canada and USA diag-
nosed from 2005 to 2012 came from a prospective study on 
host genome variants and infection.10 We excluded patients 
below 2 years of age (BMI calculations in this age group is 
not standardized), and patients with missing data on BMI at 
diagnosis (Figure 1).
2.2 | Data collection and registration
In the NOPHO‐DBH cohort data on demographics, cytoge-
netic abnormalities, and follow‐up information were prospec-
tively registered by the treating center. In Canada and USA, 
clinical research associates conducted site visits in order 
to abstract the required data from medical records. Centers 
were contacted at later time points to update follow‐up in-
formation. The Research Ethics Boards at all participating 
institutions/countries approved data collection and written 
informed consent was obtained from all patients/parents/
guardians. For Canadian children diagnosed between 1995 
and 2004, the need for informed consent was waived given 
the retrospective nature of the study.
2.3 | Definitions and statistics
BMI was calculated using height and weight measured at 
time of diagnosis. BMI standard deviation (SD) score for 
age and sex was calculated and categorized according to 
the World Health Organization Child Growth Standards11 
as following: underweight: <−2 SD, healthy weight: −2 up 
to  +2 SD for age 2‐5 and −2 up to  +1 SD for age 6‐17, 
overweight: >2 up to 3 SD for age 2‐5 and >1 up to 2 SD for 
age 6‐17, and obese: >3 SD for age 2‐5 and >2 SD for age 
127 (15%) were overweight, and 76 (9%) were obese. There was no difference in re-
lapse risk, treatment‐related mortality or overall mortality across BMI groups. The 
frequency of t(8;21) and inv(16) increased with increasing BMI. For obese patients, 
the sex, age, and country adjusted odds ratio of having t(8;21) or inv(16) were 1.9 
(95% confidence interval (CI) 1.1‐3.4) and 2.8 (95% CI 1.3‐5.8), respectively, com-
pared to healthy weight patients.
Conclusions: This study did not confirm previous reports of associations between 
overweight and increased treatment‐related or overall mortality in children. Obesity 
was associated with a higher frequency of t(8;21) and inv(16). AML cytogenetics 
appear to differ by BMI status.
K E Y W O R D S
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6‐17. For all analyses, the healthy weight group was used as 
reference.
Treatment‐related mortality was defined as death not re-
lated to disease progression.12 Patients with unknown reason 
for death were excluded from treatment‐related mortality 
analyses. Associations between BMI groups and relapse, 
treatment‐related mortality, and overall survival were inves-
tigated using the cumulative incidence function with pseudo‐
observations under competing risks and the Kaplan‐Meier 
estimator. Death was included as a competing risk in the cal-
culation of cumulative incidence of relapse, and death from 
progressive disease in the calculation of cumulative incidence 
of treatment‐related mortality. Multiple Cox regression was 
used to compare groups. Follow‐up started at diagnosis and 
ended at event, death, or last follow‐up. Cases were censored 
on November 5, 2016, 6 months before data cutoff (May 5, 
2017) to ensure independent censoring (relapse and death 
could be reported sooner than ongoing follow‐up for patients 
in continuing remission).
Inv(16)/t(16;16) (in the following referred to as 
inv(16)), t(8;21) and KMT2A rearrangements were selected 
for the study due to these abnormalities being common and 
with prognostic significance.1,13 Core‐binding factor AML, 
t(8;21) and inv(16), has generally been associated with a 
favorable prognosis, whereas the prognostic significance 
of KMT2A rearrangements depends on the fusion partner.1 
Logistic regression was used to investigate associations 
between BMI groups and cytogenetic abnormalities. Cases 
with missing data on cytogenetic abnormalities were ex-
cluded from analyses.
BMI standard deviation score as a continuous variable 
and outcomes were modeled using restricted cubic splines 
with four knots at BMI SD score −2, 0, 1, and 2.14
Confounders incorporated into statistical models were de-
fined as factors, which could influence both the independent 
variable (BMI group) and dependent variables (treatment‐
related mortality, relapse, survival, and cytogenetic abnor-
malities). Age, sex, and country group (Nordic countries, 
Belgium/the Netherlands, Hong Kong or Canada/USA) was 
included in all adjusted models. Year of diagnosis was in-
cluded in the adjusted models for treatment‐related mortality, 
relapse, and overall mortality.
3 |  RESULTS
A total of 867 patients included were treated in 10 different 
countries (Canada n = 394, Sweden n = 116, the Netherlands 
n = 92, Denmark n = 53, Finland n = 51, Hong Kong n = 50, 
Belgium n = 48, Norway n = 41, USA n = 17, and Iceland 
n = 5). Of included cases, n = 692 (80%) were population 
based, and n = 239 (28%) were included in our previously 
study of associations between BMI group and outcome.6 
The median age of diagnosis was 10  years of age (range: 
2‐17  years), 53% of cases were male and the median fol-
low‐up time for cases alive at end of follow‐up (n  =  615) 
was 3.9 years (range: 0.1‐13.3 years). Patients were treated 
on 17 different protocols with AAML0531,15 COG9421,16 
NOPHO‐AML 2004,17 DB AML‐01,18 and NOPHO‐DBH 
AML 2012 (Clini calTr ials.gov identifier: NCT01828489, 
ongoing accrual) accounting for 79%. Table 1 shows base-
line characteristics according to BMI group. The frequency 
of underweight and obesity was higher among males, and 
the median age was higher for the nonhealthy BMI groups. 
The frequency of obesity was higher in the North American 
countries.
F I G U R E  1  Study cohort and 
exclusions. The figure shows the included 
and excluded patients. The cohort was 
population based in all the specified time 
periods except for patients from Canada and 
USA diagnosed from 2005 to 2012. Patients 
with Down syndrome, acute promyelocytic 
leukemia or isolated granulocytic sarcoma 
were not included
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3.1 | BMI group and risk of relapse, 
treatment‐related mortality, and 
overall mortality
Within the follow‐up period, 324 patients suffered a first re-
lapse, 102 died from treatment‐related causes, and 244 died 
for any reason. Of the 102 patients that died from treatment‐
related causes, 42 died without previous hematopoietic stem 
cell transplantation or relapse, 14 died after hematopoietic 
stem cell transplantation in first complete remission and 46 
died after relapse from causes other than disease progression. 
In two cases, reason for death was unknown (excluded from 
treatment‐related mortality analyses). The remaining 140 
deaths were due to disease progression.
Overall, in the cohort the 5‐year cumulative incidence of 
relapse was 43% (95%‐confidence interval (CI) 40‐47), the 
5‐year cumulative incidence of treatment‐related mortality 
was 13% (95% CI 10‐15), and 5‐year overall survival was 
67% (95% CI 64‐71). The results for associations between 
BMI group and risk of relapse, treatment‐related mortality, 
and overall mortality are presented in Table 2 and Figure 2.
We found no evidence of associations between BMI group 
and risk of relapse, risk of treatment‐related mortality, or risk 
of death for any reason (Figure 2, Table 2, and Supporting 
Information). Including cytogenetic abnormalities in the 
models, as mediation analyses did not change the results 
(Table S2). Combining the overweight and obese group, we 
saw similar results with no evidence of association between 
overweight/obesity and risk of relapse, risk of treatment‐re-
lated mortality, or risk of death for any reason (Table S3).
3.2 | BMI group and cytogenetic 
abnormalities
In 36 (4.2%) cases, information on t(8;21) and inv(16) were 
missing, and in 38 (4.4%) cases information on KMT2A 
T A B L E  1  Baseline characteristics according to body mass index group
  Total cohort
Underweight
N (%)
Healthy weight
N (%)
Overweight
N (%)
Obese
N (%)
Patients 867 (100) 32 (4) 632 (73) 127 (15) 76 (9)
Sex          
Male 462 (53) 22 (5) 319 (69) 68 (15) 53 (11)
Female 405 (47) 10 (2) 313 (77) 59 (15) 23 (6)
Age          
Median (range) 10 (2‐17) 12 (2‐17) 9 (2‐17) 12 (2‐17) 13 (2‐17)
Country group          
The Nordic countries 266 (31) 11 (4) 210 (79) 28 (11) 17 (6)
The Netherlands and 
Belgium
140 (16) 6 (4) 111 (79) 17 (12) 6 (4)
Hong Kong 50 (6) 5 (10) 35 (70) 7 (14) 3 (6)
Canada and USA 411 (47) 10 (2) 276 (67) 75 (18) 50 (12)
WBC at diagnosisa          
0‐9.9 300 (35) 9 (3) 223 (74) 44 (15) 24 (8)
10‐99.9 428 (49) 14 (3) 308 (72) 62 (14) 44 (10)
≥100 137 (16) 9 (7) 99 (72) 21 (15) 8 (6)
Year of diagnosis          
1995‐1999 117 (13) 4 (3) 80 (68) 18 (15) 15 (13)
2000‐2004 130 (15) 2 (3) 85 (65) 26 (20) 16 (12)
2005‐2009 240 (28) 9 (4) 172 (72) 35 (15) 24 (10)
2010‐2014 303 (35) 13 (4) 231 (76) 42 (14) 17 (6)
2015‐2016 77 (9) 3 (4) 64 (83) 6 (8) 4 (5)
Stem cell transplanted in first 
complete remission
224 (26) 8 (25) 166 (26) 32 (25) 18 (24)
Note: Underweight: <−2 SD, Healthy weight: −2 to +2 SD for age 2‐5 and −2 to +1 SD for age 6‐17, Overweight: >2‐3 SD for age 2‐5 and >1‐2 SD for age 6‐17, 
Obesity: >3 SD for age 2‐5 and >2 SD for age 6‐17.
Abbreviation: WBC, white blood count.
a2 missing. 
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rearrangements were missing. In the remaining cases, 155 
(19%) of patients had t(8;21), 80 (10%) had inv(16) and 100 
(12%) had a KMT2A rearrangement. Patients with KMT2A 
rearrangements were younger, the three cytogenetic abnor-
mality groups showed a different pattern of white blood cell 
count at diagnoses and fewer with the cytogenetic abnormali-
ties were transplanted in first complete remission compared 
to the entire cohort (Table S4). The results for associations 
between BMI group and cytogenetic abnormalities are pre-
sented in Table 3. The frequency and odds ratio of t(8;21) 
and inv(16) increased with increasing BMI group (Table 3). 
For KMT2A rearrangements, the association with BMI group 
was less clear: overweight cases had higher frequency and 
obese cases had a lower frequency (Table 3). Figure 3 shows 
the association between BMI standard deviation score exam-
ined continuously and the adjusted odds ratio for cytogenetic 
abnormalities.
4 |  DISCUSSION
In this multinational study of 867 pediatric AML patients di-
agnosed within the last two decades, we found no evidence 
of associations between BMI group and risk of relapse, treat-
ment‐related, or overall mortality. We found associations of 
obesity and a higher frequency of t(8;21) and inv(16).
We used the World Health Organization (WHO) Child 
Growth Standard for calculating BMI SD score based on 
age and sex, due to the multinational design of our study. 
The growth standard is based on data from children from 
six different countries (Brazil, Ghana, India, Norway, 
Oman and the USA) with different ethnic backgrounds 
and cultural settings11,19 and therefore the standard is 
the most relevant when doing a multinational study. The 
WHO classification has been shown to have a higher prev-
alence of overweight and obesity but with similar trends 
when compared with the International Obesity Task Force 
and the US Centers for Disease Control and Prevention 
classifications.20
In contrast to two previous North American studies 
(including mainly patients from the US) that showed that 
overweight/obesity was associated with increased treat-
ment‐related mortality,4,5 we found no evidence of asso-
ciations between BMI group and outcome (Figure 2 and 
Table 2). There could be several explanations for the dif-
ference in results. Supportive care improves over time, 
 
Underweight
(n = 32)
Healthy 
weight 
(n = 632)
Overweight
(n = 127)
Obese
(n = 76)
Relapse        
N 14 239 46 25
5‐y cumulative incidence 
(95% CI)
52%
(32‐73%)
44%
(40‐48%)
42%
(32‐52%)
36%
(24‐48%)
Crude HR (95% CI) 1.3 (0.7‐2.1) 1 1.0 (0.7‐1.3) 0.9 (0.6‐1.3)
Adjusted HR (95% CI)a 1.2 (0.7‐2.0) 1 0.9 (0.7‐1.3) 0.7 (0.5‐1.1)
Treatment‐ related mortality        
N 4 69 17 12
5‐y cumulative incidence 
(95% CI)
13%
(0‐26%)
12%
(9‐15%)
15%
(8‐21%)
16%
(7‐25%)
Crude HR (95% CI) 1.2 (0.4‐3.3) 1 1.2 (0.7‐2.1) 1.5 (0.8‐2.7)
Adjusted HR (95% CI)a 1.2 (0.4‐3.3) 1 1.0 (0.6‐1.7) 1.1 (0.6‐2.1)
Overall mortality        
N 12 173 39 20
5‐y overall survival (95% 
CI)
63%
(42‐77%)
68%
(63‐72%)
65%
(55‐73%)
71%
(59‐81%)
Crude HR (95% CI) 1.5 (0.8‐2.6) 1 1.1 (0.8‐1.6) 1.0 (0.6‐1.6)
Adjusted HR (95% CI)a 1.4 (0.8‐2.5) 1 1.0 (0.7‐1.4) 0.8 (0.5‐1.3)
Note: Underweight: <−2 SD, Healthy weight: −2 to +2 SD for age 2‐5 and −2 to +1 SD for age 6‐17, 
Overweight: >2‐3 SD for age 2‐5 and >1‐2 SD for age 6‐17, Obesity >3 SD for age 2‐5 and >2 SD for age 
6‐17.
Abbreviations: CI: confidence interval, HR: hazard ratio
aAdjusted for age (continuously), sex, year of diagnosis (continuously), and country group (Nordic countries, 
Belgium/the Netherlands, Hong Kong, or Canada/USA). 
T A B L E  2  Relapse and survival 
according to body mass index groups
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and while all patients in the two North American studies 
were treated up to 2008, approximately half the patients 
included in our study were treated after 2008. In a previous 
study, we showed that overweight children were at higher 
risk for toxicity,6 but the mortality rate from severe toxicity 
could have decreased in recent years. Both North American 
studies included patients up to 20 years of age, whereas this 
study only included patients up to 17 years of age (upper 
age limit for the pediatric AML protocols in the NOPHO‐
DBH countries). The frequency of obesity and toxicity 
increases with age4-6 and therefore the difference in age 
distribution could be part of the explanation for difference 
in treatment‐related mortality. Due to our cohort consist-
ing of patients treated on 17 different protocols, we did not 
find it feasible to stratify on protocol. Therefore it is pos-
sible that an association between BMI group and outcome 
exist for some treatment regimes. Finally it is important to 
note that our finding of no association between BMI group 
and outcome was based on a relatively small cohort and 
therefore could be a type II error (failure to reject a false 
null hypothesis). We may have failed to show an associa-
tion between obesity and outcome because of the relatively 
low prevalence of obesity in this study, likely reflecting the 
prevalence of obesity in participating countries. If an as-
sociation between BMI and outcomes does exist, its effect 
could be magnified in countries where the prevalence of 
obesity is higher. A future meta‐analysis may overcome the 
challenges related to small sample size and the relatively 
low prevalence of obesity in this study.
The frequency of cytogenetic abnormalities in our study 
was comparable to previous reported frequencies. The fre-
quency of t(8;21) was slightly higher and the frequency of 
KMT2A rearrangement slightly lower compared to what was 
previously published,21,22 but this was probably due to these 
abnormalities being age‐dependent and the fact that children 
below 2 years were excluded from this study. Increasing BMI 
standard deviation score was associated with increasing fre-
quency of inv(16) and t(8;21) (Table 3 and Figure 3). This is 
the first rapport of associations of BMI standard deviation 
score and cytogenetic abnormalities in children, but in adults, 
obesity has been associated with AML with recurrent cytoge-
netic abnormalities (including t(8,21) and inv(16)/t(16;16)), 
though the study did not specify which cytogenetic abnor-
malities.23 Our results indicate that either a common etiology 
for overweight and certain types of AML exist or that obesity 
is associated with developing certain leukemic cytogenetic 
abnormalities.
A common variant in the gene coding for the fat mass‐ and 
obesity‐associated protein (FTO) is known to predispose to 
obesity in adults and children.24 Recently, it has been shown 
that FTO, an RNA demethylase, plays an oncogenic role in 
AML in adults.25 It might therefore be biologically plausible 
that obesity and (certain types of) AML could have a com-
mon etiology in children as well.
If, instead, obesity is associated with developing core‐
binding factor leukemia, it is possible that obese children 
have a higher risk of developing AML, comparable to 
obese adults.26,27 A recent study showed that bone marrow 
adipocytes support the survival and proliferation of AML 
F I G U R E  2  Cumulative incidence of relapse, treatment‐related 
mortality, and overall survival according to body mass index group. 
A, Cumulative incidence of relapse. B, Cumulative incidence of 
treatment‐related mortality (TRM). C, Kaplan‐Meier estimator of 
overall survival
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blasts.28 Also, there is growing evidence that higher birth‐
weight is associated with developing both acute lymphoid 
leukemia and AML in childhood and young adulthood,29 
but studies of associations between birth‐weight and cyto-
genetic subgroups of AML are lacking. However, it is im-
portant to note, that this study was not designed to examine 
the effect of obesity on the risk of developing leukemia. 
Studies of incidence of AML in overweight children com-
pared to healthy weight children are needed in general, and 
with a focus on specific cytogenetic subtypes in particular. 
As opposed to our study, future studies would also benefit 
from collecting BMI SD score at several time points before 
AML diagnosis.
Ethnicity could be a confounder in this study. Gramatges 
et al demonstrated a higher frequency of t(8;21) in Hispanic 
children with AML compared to non‐Hispanic whites.30 
However, the study did not show frequency of overweight in 
the two groups, and Hispanic children are more overweight in 
the US.31 We did not have information on ethnicity for about 
half our cases, and because of our multinational cohort, eth-
nicity groups were difficult to define. Therefore, we chose not 
to include ethnicity in our models. As a very crude marker for 
ethnicity, we adjusted cytogenetic abnormality analyses for 
country group and did not find considerable differences with 
crude estimates (Table 3). Environmental factors could also 
be a cause of both overweight and cytogenetic abnormalities, 
but knowledge is lacking.
We did not find evidence that the increased frequency 
of core‐binding factor leukemia with increasing BMI 
standard deviations score led to improved outcome. Yet, 
although the estimates are quite imprecise with wide 
confidence intervals, we did observe a decreased risk 
of relapse with increasing BMI standard deviation score 
(Table 2 and Figure S1).
Our study needs to be interpreted in light of certain lim-
itations. We only had information on BMI at diagnosis and 
therefore could not investigate effect of weight change on 
outcome, a factor which has been associated with outcome 
in pediatric acute lymphoblastic leukemia.32-34 The North 
American cohort was created for studies on infectious com-
plications in pediatric AML,10,35-37 and not for studies on 
outcome and therefore follow‐up is short for some patients. 
The patients included in the study were treated within a 
rather large timeframe (1995‐2016) on 17 different protocols, 
which makes the cohort relatively heterogeneous. However, 
despite differences in protocols they all included cytarabine 
(cumulative dose from 20 to 85 g/m2), one or more anthra-
cyclines (daunorubicin/idarubicin or mitoxantrone or both), 
and most included etoposide. We did not have information 
on socioeconomic status. Socioeconomic status has been 
shown to be associated with risk of overweight in western 
developed countries38 and outcome from pediatric AML in 
the USA.39 But since healthcare costs are tax‐covered for al-
most all included countries (only 17 included patients were 
from USA), the effect of socioeconomic status on outcome 
may be smaller in our cohort, than in the USA. We speculate 
that the effect of socioeconomic status on outcome in the 
USA could be part of the explanation for the discrepancy in 
results between this and the two previous North American 
studies.4,5
In conclusion, in this large multinational cohort, we found 
that, in children with AML, overweight and obesity were not 
  Underweight Healthy weight Overweight Obese
t(8;21)        
N (%) 2 (7) 106 (17) 26 (21) 21 (31)
Crude OR (95% CI) 0.3 (0.08‐1.4) 1 1.2 (0.8‐2.0) 2.1 (1.2‐3.7)
Adjusted OR (95% CI)a 0.3 (0.08‐1.4) 1 1.2 (0.7‐1.9) 1.9 (1.1‐3.4)
inv(16)/t(16;16)        
N (%) 1 (3) 53 (9) 14 (11) 12 (18)
Crude OR (95% CI) 0.4 (0.05‐2.7) 1 1.3 (0.7‐2.5) 2.2 (1.1‐4.4)
Adjusted OR (95% CI)a 0.3 (0.05‐2.6) 1 1.6 (0.8‐3.0) 2.8 (1.3‐5.8)
KMT2A rearrangements        
N (%) 5 (17) 70 (12) 22 (18) 3 (4)
Crude OR (95% CI) 1.5 (0.6‐4.1) 1 1.7 (1.0‐2.8) 0.4 (0.1‐1.2)
Adjusted OR (95% CI)a 1.8 (0.6‐4.9) 1 2.0 (1.1‐3.5) 0.5 (0.1‐1.5)
Note: Underweight: <−2 SD, Healthy weight: −2 to +2 SD for age 2‐5 and −2 to +1 SD for age 6‐17, 
Overweight: >2‐3 SD for age 2‐5 and >1‐2 SD for age 6‐17, Obesity >3 SD for age 2‐5 and >2 SD for age 
6‐17.
Abbreviations: CI: confidence interval, OR: odds ratio.
aAdjusted for age (continuously), sex and country group (Nordic countries, Belgium/the Netherlands, Hong 
Kong, or Canada/USA). 
T A B L E  3  Cytogenetic abnormalities 
according to body mass index groups
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associated with outcome, which is in contrast to previous 
studies. We found that obesity was associated with a higher 
frequency of core‐binding factor leukemia. This finding 
raises the question whether overweight in children increases 
the risk of developing core‐binding factor AML, but further 
studies are needed.
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